
#### 10th March 2016

TMT

### Altran Technologies

### Price EUR10.85

Bloomberg Reuters 12-month High Market Cap (EU Ev (BG Estimate Avg. 6m daily vo 3y EPS CAGR	ALT FP ALTR.PA 12.6 / 8.4 1,907 2,030 273.9 15.7%			
	1 M	3 M	6 M 3	1/12/15
Absolute perf.	6.6%	-11.1%	5.8%	-12.1%
Softw.& Comp.	6.6%	-4.4%	10.6%	-5.5%
DJ Stoxx 600	9.6%	-6.9%	-6.8%	-7.3%
YEnd Dec. (€m)	2014	2015e	2016e	2017e
Sales	1,756	1,945	2,095	2,213
% change		10.8%	7.7%	5.6%
EBITDA	183	204	237	269
EBIT	132.0	158.0	180.0	208.0
% change		19.7%	13.9%	15.6%
Net income	106.0	121.0	142.0	163.0
% change		14.2%	17.4%	14.8%
	2014	2015e	2016e	2017e
Operating margin	9.4	9.5	10.2	11.0
Net margin	4.7	5.2	5.5	6.1
ROE	11.7	12.9	13.6	14.6
ROCE	15.8	14.6	17.6	20.1
Gearing	6.0	16.0	4.0	-6.0
(€)	2014	2015e	2016e	2017e
EPS	0.60	0.69	0.81	0.93
% change	-	15.0%	17.4%	14.8%
P/E	18.1x	15.7x	13.4x	11.7x
FCF yield (%)	5.6%	4.7%	6.3%	7.5%
Dividends (€)	0.15	0.20	0.25	0.30
Div yield (%)	1.4%	1.8%	2.3%	2.8%
EV/Sales	1.1x	1.0x	0.9x	0.8x
EV/EBITDA	10.7x	10.0x	8.2x	6.9x
EV/EBIT	11.8x	11.0x	9.1x	7.6x



### FY15 results in line with expectations, positive outlook

### Fair Value EUR13 (+20%)

This morning Altran reported FY15 results in line with expectations, with an operating margin of 9.6%. Excluding Germany, the margin would have stood at 11.3%. Free cash flow was down 20% as expected, to EUR92m and in line with our estimate. The outlook statement for 2016 is positive, while the "Altran 2020 Ignition" plan is progressing well. Finally, the dividend is raised by 27% to EUR0.19/share. We expect the share price to react slightly positively in the short term.

#### ANALYSIS

- FY15 operating margin in line with expectations. For 2015, Altran has reported sales up 10.5% (+4.1% lfl) to EUR1,945m, operating margin up 13.1% to EUR185.9m or 9.6% of sales (+0.2ppt), EBIT up 17.6% to EUR155m after EUR25.5m in non-recurring costs (including EUR10m restructuring costs for Germany and a EUR7m provision for litigation), and net profit was up 22% to EUR100.5m. Operating margin was 1% above our forecast (EUR183.9m or 9.5% of sales) and fully in line with the consensus (EUR186m or 9.6% of sales). We expected EBIT of EUR157.6m and net profit of EUR100.4m (consensus: EUR161m and EUR101m). Gross margin was up 0.1ppt to 28.7% thanks to an average invoicing rate up 0.7ppt to 87.2%. On their side, SG&A costs grew by 10% and declined as a percentage of sales (19.1%, vs. 19.3% in 2014 and 20.7% in 2011). Excluding Germany, operating margin would have been 1.7ppt above the reported level, at 11.3%. We estimate losses in Germany at EUR8.8m, slightly below our forecast (BG est.: EUR10m).
- Free cash flow unsurprisingly down 20%, and above FY15 target. Free cash flow was down 20% to . EUR92m or 4.7% of sales (vs. 6.5% in 2014), which was however above the target set for 2015 (4%) and in line with our expectations (EUR89m, vs. consensus EUR95m). The goal for 2020 remains 7% of sales. Free cash flow in 2014 was inflated by EUR15m of one-offs due to the catch-up effect from delayed payments in 2013. DSOs fell by 3.5 days in 2015 to 77.5 days from 81 days. Consequently, net debt on 31<sup>st</sup> December 2015 was up EUR101m to EUR138.3m - after EUR168m disbursed on acquisitions, EUR26m dividends and EUR11m share buy-backs -, which was EUR14m above our estimate (EUR124m) but pretty in line with the consensus average (EUR133m).
- Positive outlook for 2016, Altran 2020 Ignition progressing well. As usual, Altran does not report any formal guidance. In its statement, management expects that 2016 will be another year of profitable growth. At this stage, we forecast 5.3% Ifl revenue growth with an op. margin of 10.2% (consensus: 10.3%). In addition, the "Altran 2020 Ignition" strategic plan is progressing well. In 2016, Altran will launch the transformation process in the key levers of the plan (augmented value services, industrialisation and offshoring, expansion in the U.S., Germany and India, and continuous operational improvement). In augmented value services, Altran now has five "World Class Centers" up and running, and five new ones will be launched in 2016.

#### VALUATION

- Altran's shares are trading at est. 9.1x 2016 and 7.6x 2017 EV/EBIT multiples.
- Net debt on 31st December 2015 was EUR138.3m (net gearing: 19%).

### NEXT CATALYSTS

Analysts' meeting today at 9am CET / 8am BST / 4am EDT in Neuilly-sur-Seine (96 avenue Charles de Gaulle).

Click here to download



Analyst : Gregory Ramirez 33(0) 1 56 68 75 91 gramirez@bryangarnier.com Sector Team : **Richard-Maxime Beaudoux** Thomas Coudry **Dorian Terral** 

### BRYAN, GARNIER & CO

BUY

## Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

#### Stock rating

DIN/	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a				
BUY	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of				
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock				
	will feature an introduction outlining the key reasons behind the opinion.				

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

#### Distribution of stock ratings

BUY ratings 64,4%

NEUTRAL ratings 28,1%

SELL ratings 7,4%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	reholding Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	
2	Issuer shareholding in Bryan Garnier	an The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement		
7	Research agreement A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.		No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.		No
12	Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.		No
13	Bryan Garnier executive is an officer A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.		No
14	Analyst disclosure The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.		Yes
15	5 Other disclosures Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).		No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

### BRYAN, GARNIER & CO

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudential et de		FINMA	
(FCA)	resolution (ACPR)			

#### Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever. Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

### BRYAN, GARNIER & CO